China’s Sino Biopharmaceutical has partnered with Boehringer Ingelheim in a licensing deal potentially worth $7.4 billion to bolster its cancer-focused drug development efforts. The collaboration covers six early-stage programs aimed at advancing next-generation oncology therapies.
Under the terms of the agreement, Boehringer will pay $358 million upfront for access to the six biologic programs, with Sino eligible for up to $7 billion in milestone payments and additional royalties on sales of any commercialized products.
Sino will lead early-stage development before transferring the programs to Boehringer once agreed clinical milestones are achieved. Boehringer will then have the option to secure exclusive rights to further develop, manufacture, and commercialize the candidates.
For four programs, Boehringer will obtain rights outside mainland China, Hong Kong, and Macau, while the remaining two will carry global commercialization rights. Five of the six programs will come from Sino’s subsidiary LaNova Medicines, while Beijing Tide, another subsidiary of the Chinese pharmaceutical group, will develop the sixth.
The collaboration will focus on antibody-drug conjugates and T-cell engagers. These types of treatments have attracted growing interest from pharmaceutical companies seeking targeted cancer treatments that deliver cytotoxic drugs directly to cancer cells.
T-cell engagers are gaining attention as companies seek to extend their application beyond blood cancers. These immunotherapies work by bringing cancer cells and immune cells into close proximity, enabling the immune system to recognize and attack tumors.
Boehringer’s innovation unit head, Paola Casarosa, said the partnership combines complementary research capabilities to strengthen the company’s development portfolio. The agreement follows Boehringer’s opening of a new research and development centre in Shanghai in October, reinforcing its investment in China’s pharmaceutical innovation ecosystem.
Western drugmakers, including Sanofi, GSK, and AstraZeneca, have also signed licensing agreements with Sino Biopharmaceutical in 2026, although their potential deal values were below $2 billion. This latest agreement reflects the growing importance of Chinese biotechnology companies as sources of early-stage drug candidates for multinational pharmaceutical groups.
A 2025 report by GlobalData found that China-based companies accounted for 20% of drugs in development worldwide. China has also outlined an ambitious five-year strategy for its biomedical industry, focusing on increasing the development of original medicines and strengthening its global competitiveness.
Leave a Reply